BIOABioAge Labs, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet and comfortable debt (AA), but big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -88% · now 74% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can BIOA take a bad year?
BioAge Labs, Inc. holds $319M more cash than debt, and is burning $22M a quarter, about 3.6 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 24.91
Altman Z-score · safe zone, above 3
- Cash runway
- 3.6 years
Cash runway · burning $22M a quarter at the current rate
Details›
- Total debtQ2 2026
- $0
- Cash and short-term investments
- $319M
- Net cash
- $319M
- Operating profit, trailing twelve months
- −$106M
- Debt / equity
- 0.00×
- Annualised volatilitytwo years of daily moves
- 102%
- Worst drawdown on file
- −88%
- Below its 52-week high
- 74%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry